The Inhibitory Effect of Recombinant Human Soluble Thrombomodulin on Initiation and Extension of Coagulation

 

 Buy Article Permissions and Reprints

Summary

Recombinant human soluble thrombomodulin (rhsTM) was compared with various anticoagulants for in vitro anticoagulant effects on thrombin generation, clotting time, and thromboelastography. rhsTM as well as APC reduced the level of the peak of the thrombin generation curve, but we did not observe any time-delay to reach the peak. This effect of rhsTM was diminished in PC-deficient plasma and was closely associated with the inhibitory effect on prothrombinase and factor Va. On the other hand, hirudin and argatroban delayed the time to reach the level of the peak, without reducing it. rhsTM and other anticoagulants except for activated protein C (APC) were found to have concentration-dependent anticoagulant activity by conventional clotting tests. However, the concentration of rhsTM for clotting time was slightly affected by anti-protein C antibody. Moreover, the concentration of rhsTM required to inhibit thrombin activity directly was 50 times higher than that needed to inhibit thrombin generation. The effect of rhsTM on clot development was compared with that of other anticoagulants by thromboelastography; rhsTM reduced the growth of the clot but had little effect on the time to activate clotting, while the other anticoagulants had the opposite effect. This effect of rhsTM was completely abolished by the addition of anti-protein C or anti-protein S antibody.

These findings suggest that rhsTM attenuates blood clotting by reducing the level of generated thrombin through protein C activation and subsequent factor Va inactivation and prothrombinase inhibition.

• References

• 1 Hemker HC. Thrombin generation, an essential step in haemostasis and thrombosis. In: Haemostasis and Thrombosis 3rd edition. Bloom AL, Forbes CD, Thomas DP, Tuddenham EGD. eds. Edinburgh, UK: Churchill Livingstone; 1994: 477-90.
  Google Scholar
• 2 James HL. Physiology and biochemistry of prothrombin. In: Haemostasis and Thrombosis 3rd edition. Bloom AL, Forbes CD, Thomas DP, Tuddenham EGD. eds. Edinburgh, UK: Churchill Livingstone; 1994: 397-438.
  Google Scholar
• 3 Rosing J, Tans G. Coagulation factor V: An old star shines again. Thromb Haemost 1997; 78: 427-33.
  Article in Thieme ConnectPubMedGoogle Scholar
• 4 Rand MD, Lock JB, van’t Veer C, Gaffney DP, Mann KG. Blood clotting in minimally altered whole blood. Blood 1996; 88: 3432-45.
  PubMedGoogle Scholar
• 5 Thorelli E, Kaufman RJ, Dahlbäck B. Cleavage requirements of factor V in tissue-factor induced thrombin generation. Thromb Haemost 1998; 80: 92-8.
  Article in Thieme ConnectPubMedGoogle Scholar
• 6 Kumar R, Beguin S, Hemker HC. The inflluence of fibrinogen and fibrin on thrombin generation-evidence for feedback activation of the clotting system by clot bound thrombin. Thromb Haemost 1994; 72: 713-21.
  Article in Thieme ConnectPubMedGoogle Scholar
• 7 Francis WC, Markham ER, Barlow HG, Florack MT, Dobrzynski MD, Marder JV. Thrombin activity of fibrin thrombi and soluble plasmic derivatives. J Lab Clin Med 1983; 102: 220-30.
  PubMedGoogle Scholar
• 8 Callas D, Fareed J. Comparative pharmacology of site directed antithrombin agents. Implication in drug development. Thromb Haemost 1995; 74: 473-81.
  Article in Thieme ConnectPubMedGoogle Scholar
• 9 Kelly AB, Marzec UM, Krupski W, Bass A, Cadroy Y, Hanson SR, Harker LA. Hirudin interruption of heparin-resistant arterial thrombus formation in baboons. Blood 1991; 77: 1006-12.
  PubMedGoogle Scholar
• 10 Lunven C, Gauffeny C, Lecoffre C, O’Brien DP, Roome NO, Berry CN. Inhibition by Argatroban, a specific thrombin inhibitor, of platelet activation by fibrin clot-associated thrombin. Thromb Haemost 1996; 75: 154-60.
  Article in Thieme ConnectPubMedGoogle Scholar
• 11 Lu D, Kalafatis M, Mann KG, Long GL. Comparison of activated protein C/protein S-mediated inactivation of human factor VIII and factor V. Blood 1996; 87: 4708-17.
  PubMedGoogle Scholar
• 12 Barrowcliffe TW, Thomas DP. Heparin and low molecular weight heparin. In: Haemostasis and Thrombosis 3rd edition. Bloom AL, Forbes CD, Thomas DP, Tuddenham EGD. eds. Edinburgh, UK: Churchill Livingstone; 1994: 1417-38.
  Google Scholar
• 13 Gomi K, Zushi M, Honda G, Kawahara S, Matsuzaki O, Yamamoto S, Maruyama I, Suzuki K. Antithrombotic effect of recombinant human thrombomodulin on thrombin-induced thromboembolism in mice. Blood 1990; 75: 1396-9.
  PubMedGoogle Scholar
• 14 Ohishi R, Watanabe N, Aritomi M, Gomi K, Kiyota T, Yamamoto S, Ishida T, Maruyama I. Evidence that the protein C activation pathway amplifies the inhibition of thrombin generation by recombinant human thrombomodulin in plasma. Thromb Haemost 1993; 70: 423-6.
  Article in Thieme ConnectPubMedGoogle Scholar
• 15 Mohri M, Gonda Y, Oka M, Aoki Y, Gomi K, Kiyota T, Sugihara T, Yamamoto S, Ishida T, Maruyama I. The antithrombotic effects of recombinant human soluble thrombomodulin (rhsTM) on tissue factor-induced disseminated intravascular coagulation in crab-eating monkeys (Macaca fascicularis). Blood Coagul Fibrinolysis 1997; 8: 274-83.
  CrossrefPubMedGoogle Scholar
• 16 Mohri M, Sata M, Gomi K, Maruyama Y, Osame M, Maruyama I. Abnormalities in the protein C anticoagulant pathway detected by a novel assay using human thrombomodulin. Lupus 1997; 6: 590-6.
  CrossrefPubMedGoogle Scholar
• 17 Mohri M, Suzuki M, Sugimoto E, Sata M, Yamamoto S, Maruyama I. Effects of recombinant human soluble thrombomodulin (rhs-TM) on clot-induced coagulation in human plasma. Thromb Haemost 1998; 80: 925-9.
  Article in Thieme ConnectPubMedGoogle Scholar
• 18 Harker LA, Marzec UM, Mohri M, Fernandez JA, Kelly AB, Hanson SR, Esmon CT, Griffin JH. Antithrombotic efficacy and safety of recombinant human soluble thrombomodulin in non-human primates: inactivation of thrombin and enhanced generation of activated protein C. Circulation (submitted)..
  PubMedGoogle Scholar
• 19 Nakashima M, Uematsu T, Umemura K, Maruyama I, Tsuruta K. A novel recombinant human soluble thrombomodulin, ART-123, activates the protein C pathway in healthy male volunteers. J Clin Pharmacol 1998; 38: 540-4.
  CrossrefPubMedGoogle Scholar
• 20 Chandler WL. The thromboelastograph and the thromboelastography technique. Semin Thromb Hemost 1996; 21 (Suppl. 04) 1-6.
  Article in Thieme ConnectPubMedGoogle Scholar
• 21 Ichihara K. Comparison of two regression parameters. In: Statistics of bioscience – practical technique and theory. Tokyo, Japan: Nankodo; 1990: 218-23.
  Google Scholar
• 22 Prasa D, Svendsen L, Sturzebecher J. The ability of thrombin inhibitors to reduce the thrombin activity generated in plasma on extrinsic and intrinsic activation. Thromb Haemost 1997; 77: 498-503.
  Article in Thieme ConnectPubMedGoogle Scholar
• 23 Callas DD, Hoppensteadt D, Fareed J. Comparative studies on the anticoagulant and protease generation inhibitory actions of newly developed site-directed thrombin inhibitory drugs. Efegatran, argatroban, hirulog, and hirudin. Semin Thromb Haemost 1995; 21: 177-83.
  Article in Thieme ConnectPubMedGoogle Scholar
• 24 Nicolaes GAF, Thomassen MCLGD, Tans G, Rosing J, Hemker HC. Effect of activated protein C on thrombin generation and on the thrombin potential in plasma of normal and APC-resistant individuals. Blood Coagul Fibrinolysis 1997; 8: 28-38.
  CrossrefPubMedGoogle Scholar
• 25 Hemker HC, Beguin S. Thrombin generation in plasma: Its assessment via the endogenous thrombin potential. Thromb Haemost 1995; 74: 134-8.
  Article in Thieme ConnectPubMedGoogle Scholar